Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277145 | 0.84 | SLC6A4 (0.41) | SLC6A4MAOBLTA4HPTGS2 | |
| SCHEMBL4326032 | 0.83 | NPY1R (0.50) | NFE2L2SIGMAR1LTA4H | |
| SCHEMBL935234 | 0.79 | NPY1R (0.50) | SLC6A4 | |
| SCHEMBL935709 | 0.79 | NPY1R (0.50) | SLC6A4 | |
| SCHEMBL30674540 | 0.79 | NFE2L2 (0.70) | NFE2L2HRH3 | |
| Formic Acid SCHEMBL1277213 | 0.78 | PPARG (0.41) | SLC6A4 | |
| SCHEMBL28283793 | 0.77 | NPY1R (0.57) | — | |
| SCHEMBL1277158 | 0.76 | SLC6A4 (0.44) | SLC6A4 | |
| SCHEMBL9770319 | 0.76 | DRD4 (0.59) | HRH3 | |
| SCHEMBL1345118 | 0.73 | MAOB (0.57) | MAOBLTA4HPTGS2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |